Participated · Series A · Feb 2026

BCIFlex (also referred to as Zhiran Medical in the source article) focuses exclusively on invasive brain–computer interface (BCI) technology that implants stretchable, flexible electrodes directly into the cerebral cortex. Its core ‘high-throughput, stretchable flexible electrode’ platform is designed to record and write neural signals with high temporal and spatial resolution while minimizing long-term tissue damage. Building on this hardware, the company has produced a wireless invasive BCI system and is concurrently advancing proprietary neuron chips, decoding algorithms, and an electrode-implantation robot. BCIFlex has established nearly 2,000 m² of micro- and nanofabrication space plus a GMP-standard assembly line to retain full control over clinical-grade manufacturing. The firm completed clinical implantation of >100-channel invasive BCI products in 2025, preliminarily confirming safety and efficacy, and plans to launch large-scale registration clinical trials in 2026. Government policy support for BCI in China and new medical reimbursement codes are expected to accelerate adoption of the company’s technology. Financially, BCIFlex has attracted back-to-back nine-figure Series A and A+ rounds within six months, underscoring investor confidence in its technical depth and commercialization roadmap.

Participated · Series A · Dec 2023

White Rabbit Video is a short-video MCN that runs four main businesses: short video, live e-commerce, Douyin (TikTok China) agency operations, and brand marketing. The company has incubated prominent creators, most notably Luo Wangyu (骆王宇), who has over 6.6 million Douyin followers and ranked atop the “Xingtu” recommendation list for four consecutive weeks. A single video from its creators has achieved over RMB 13 million in sales. White Rabbit Video has signed nearly one thousand KOLs, including 骆王宇, 丁七七, 袁大帅, 情绪唱片, 戴较瘦, 戏精实验室, and 三维地图看世界. The company’s current financing event is an A+ round of nearly RMB 100 million, indicating recent external investor interest. No additional future plans or financial metrics were disclosed in the article.